0
Signin
countryflagUS

18889881171

AAPL 190.415 0.3663% MSFT 422.65 -0.1016% GOOG 175.36 0.8512% GOOGL 174.14 0.9449% AMZN 185.71 -0.1505% NVDA 943.46 -0.3001% META 473.555 -1.6582% TSLA 174.87 0.5058% TSM 154.06 -0.977% LLY 776.1758 -1.3779% V 280.145 -0.2972% AVGO 1436.4972 0.0228% JPM 204.205 1.0366% UNH 522.225 0.9033% NVO 133.03 -1.2105% WMT 63.485 6.109% LVMUY 170.79 -0.2511% XOM 117.87 -0.5988% LVMHF 855.728 -0.1473% MA 461.6867 0.805%

Palisade Bio Inc

Healthcare US PALI

6.24USD
-0.14(2.19%)

Last update at 2024-05-16T16:47:00Z

Day Range

5.956.29
LowHigh

52 Week Range

0.508.54
LowHigh

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -14.26000M -26.61600M -10.32200M -8.35165M -4.92462M
Minority interest - - - - -
Net income -12.79900M -27.27100M -10.57000M -8.35165M -4.92462M
Selling general administrative 8.76M 9.31M 6.20M 4.59M 4.56M
Selling and marketing expenses - - - - -
Gross profit - - 0.01M 0.02M 0.26M
Reconciled depreciation 0.00300M 0.00200M 0.00300M - -
Ebit -15.72100M -41.85400M -9.29700M -8.34273M -4.91692M
Ebitda -15.15000M -44.28100M -10.12200M -8.19887M -4.73112M
Depreciation and amortization 0.57M -2.42700M -0.82500M 0.14M 0.19M
Non operating income net other - - - - -
Operating income -15.72100M -41.85400M -9.29700M -8.63169M -8.25946M
Other operating expenses 15.31M 41.85M 9.30M 8.65M 8.52M
Interest expense 0.01M 2.40M 0.23M 0.00892M 0.00770M
Tax provision - - - - -
Interest income - - 0.03M 0.56M 3.34M
Net interest income -0.01300M -3.08400M -1.07600M - -
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -1.46100M 0.66M 0.25M 0.29M 3.34M
Total revenue 0.00000M 0.00000M 0.01M 0.02M 0.26M
Total operating expenses 15.31M 41.85M 9.30M 8.65M 8.52M
Cost of revenue - - - - -
Total other income expense net 1.46M 15.24M -1.02500M 0.28M 3.33M
Discontinued operations - - - - -
Net income from continuing ops -14.26000M -26.61600M -10.32200M - -
Net income applicable to common shares -14.54800M -26.61600M -10.32200M -10.06400M -4.48400M
Preferred stock and other adjustments - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Total assets 15.76M 12.51M 3.02M 6.58M 7.68M
Intangible assets - - 0.15M 0.67M 0.76M
Earning assets - - - - -
Other current assets 2.35M 1.88M 2.35M 0.51M 0.36M
Total liab 3.28M 5.15M 19.62M 1.46M 1.63M
Total stockholder equity 12.48M 7.37M -16.60200M 5.13M 6.05M
Deferred long term liab - - 1.82M - -
Other current liab 0.99M 0.78M 3.31M 0.14M 0.22M
Common stock 0.03M 0.14M 0.03M 0.04M 0.18M
Capital stock 0.03M 0.14M 0.03M - -
Retained earnings -109.19000M -94.64200M -68.02600M -221.97554M -213.62389M
Other liab - 2.65M 1.83M - 0.18M
Good will - - - - -
Other assets - 0.03M 0.16M 0.03M 0.02M
Cash 12.38M 10.49M 0.71M 5.11M 5.79M
Cash and equivalents - - - - -
Total current liabilities 3.01M 2.50M 8.08M 1.22M 1.05M
Current deferred revenue - - - - -
Net debt -11.97900M -10.29600M 0.71M -4.70171M -5.78711M
Short term debt 0.19M 0.20M 1.22M 0.26M -
Short long term debt 0.09M 0.09M 1.05M - -
Short long term debt total 0.40M 0.20M 1.42M 0.41M -
Other stockholder equity 121.64M 101.86M 51.39M 228.01M 220.38M
Property plant equipment - 0.11M 0.28M 0.42M 0.00500M
Total current assets 14.73M 12.37M 0.90M 5.65M 6.51M
Long term investments - - - - -
Net tangible assets - 7.36M -16.60200M -8.33200M -45.19800M
Short term investments - - - - -
Net receivables 1.44M 0.15M 0.06M 0.02M 0.36M
Long term debt - - 0.09M - -
Inventory -1.43800M -0.15000M -2.22755M - -
Accounts payable 1.83M 1.52M 3.56M 0.82M 0.83M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - -0.00073M -0.95042M -0.90226M
Additional paid in capital - - - - -
Common stock total equity - - 0.17M 0.04M 0.18M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.72M 0.03M 1.84M - 0.32M
Deferred long term asset charges - - - - -
Non current assets total 1.03M 0.14M 2.12M 0.94M 1.18M
Capital lease obligations 0.32M 0.11M 0.28M - -
Long term debt total - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -0.01000M -0.05400M -0.00600M - -
Change to liabilities - -2.39500M 1.01M 0.84M 0.09M
Total cashflows from investing activities - -0.05400M -0.00600M -0.00600M -0.00500M
Net borrowings - -0.18300M 1.98M -0.22000M 1.36M
Total cash from financing activities 15.26M 24.61M 1.89M 6.59M 1.81M
Change to operating activities - -2.44500M 1.44M -0.74400M 0.25M
Net income -14.26000M -26.61600M -10.32200M -8.35165M -4.92462M
Change in cash 1.89M 9.78M -2.88400M -0.67219M -0.88783M
Begin period cash flow 10.52M 0.74M 3.62M 5.79M 6.67M
End period cash flow 12.41M 10.52M 0.74M 5.11M 5.79M
Total cash from operating activities -13.36000M -14.77300M -4.76800M -7.25568M -7.69242M
Issuance of capital stock 14.40M 25.11M 1.18M - -
Depreciation 0.00300M 0.00200M 0.00300M 0.14M 0.19M
Other cashflows from investing activities - - - - 5.00M
Dividends paid - - - - -
Change to inventory - - - 0.02M 0.04M
Change to account receivables - 0.08M -0.09521M 0.27M 0.02M
Sale purchase of stock - - 14.70M 6.55M 1.83M
Other cashflows from financing activities 1.65M 20.83M 0.74M 0.41M 0.35M
Change to netincome - 14.26M 2.96M 2.78M 1.34M
Capital expenditures 0.01000M 0.00000M 0.00600M 0.00600M 0.00171M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 1.25M -4.75600M 2.39M -1.03510M -5.47700M
Stock based compensation 1.03M 1.89M 2.01M 0.88M 0.63M
Other non cash items -1.38500M 34.77M 1.19M 1.11M 1.89M
Free cash flow -13.37000M -14.77300M -4.77400M -7.25568M -7.69413M

Fundamentals

  • Previous Close 6.38
  • Market Cap5.51M
  • Volume14148
  • P/E Ratio1.87
  • Dividend Yield-%
  • EBITDA-13.39600M
  • Revenue TTM0.25M
  • Revenue Per Share TTM0.05
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM0.32

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to EBITDA (x)
PALI
Palisade Bio Inc		 -0.14 2.19% 6.24 1.87 - 21.46 0.39 0.73
NVO
Novo Nordisk A/S		 -1.63 1.21% 133.03 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 0.57 0.43% 132.69 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 1.20 0.27% 438.69 30.40 24.75 10.68 6.25 9.52 20.36
CSLLY
CSL Ltd		 1.03 1.09% 96.00 42.45 26.95 7.05 5.80 7.85 26.51

Reports Covered

Stock Research & News

View All

Profile

Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is LB1148, an oral liquid formulation of the digestive enzyme inhibitor tranexamic acid to reduce the formation of postoperative adhesions, postoperative ileus, and return of bowel function in adults. It has a license agreement with the Regents of the University of California; and co-development and distribution agreement with Newsoara Biopharma Co., Ltd. Palisade Bio, Inc. is based in Carlsbad, California.

Palisade Bio Inc

5800 Armada Drive, Carlsbad, CA, United States, 92008

Key Executives

Name Title Year Born
Mr. J. D. Finley Interim CEO & CFO 1957
Ms. Sharon McBrayer Director of Operations NA
Mr. Robert C. McRae Sr. VP of Operations & Strategic Devel. NA
Dr. Herbert B. Slade FAAAAI, M.D. Chief Medical Officer NA
Mr. Ryker Willie VP of Fin. & Corp. Controller NA

Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).